Rigel Pharmaceuticals Stock Today
| RIGL Stock | USD 26.04 1.00 3.99% |
Performance14 of 100
| Odds Of DistressOver 62
|
Rigel Pharmaceuticals is selling for 26.04 as of the 23rd of November 2024. This is a 3.99 percent increase since the beginning of the trading day. The stock's lowest day price was 25.34. Rigel Pharmaceuticals has more than 62 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Rigel Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of November 2000 | Category Healthcare | Classification Health Care |
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. The company has 17.61 M outstanding shares of which 661.19 K shares are at this time shorted by private and institutional investors with about 3.91 trading days to cover. More on Rigel Pharmaceuticals
Moving against Rigel Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Rigel Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Raul Rodriguez | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRigel Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rigel Pharmaceuticals' financial leverage. It provides some insight into what part of Rigel Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rigel Pharmaceuticals (RIGL) is traded on NASDAQ Exchange in USA. It is located in 611 Gateway Blvd, South San Francisco, CA, United States, 94080 and employs 147 people. Rigel Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 458.69 M. Rigel Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 17.61 M outstanding shares of which 661.19 K shares are at this time shorted by private and institutional investors with about 3.91 trading days to cover.
Rigel Pharmaceuticals currently holds about 81.64 M in cash with (5.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Check Rigel Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationRigel Pharmaceuticals owns a total of 17.61 Million outstanding shares. Over half of Rigel Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Rigel Ownership Details
Rigel Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-09-30 | 144.3 K | |
| Renaissance Technologies Corp | 2024-09-30 | 141.9 K | |
| Ing Investment Management Llc | 2024-06-30 | 118.9 K | |
| Jane Street Group Llc | 2024-06-30 | 105.9 K | |
| Ubs O'connor Llc | 2024-06-30 | 92.4 K | |
| Kennedy Capital Management Inc | 2024-06-30 | 89.9 K | |
| Squarepoint Ops Llc | 2024-06-30 | 80.9 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 77.4 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 75.6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.8 M | |
| Armistice Capital, Llc | 2024-06-30 | 1.6 M |
Rigel Pharmaceuticals Historical Income Statement
Rigel Stock Against Markets
Rigel Pharmaceuticals Corporate Management
| Raymond JD | General VP | Profile | |
| Tarek Sallam | Vice Marketing | Profile | |
| David Santos | Executive Officer | Profile | |
| Julie Patel | Senior Resources | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.